2016
DOI: 10.4238/gmr.15038325
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis

Abstract: ABSTRACT. This meta-analysis study aimed to investigate the correlation between CD44-positive cancer stem cells (CSCs) and clinicopathological features and its effect on the survival of ovarian cancer patients. A comprehensive literature search in the electronic databases, including PubMed, EMBASE, and Wanfang (up to December 1, 2015), was conducted. Publications assessing the clinical or prognostic significance of CD44 expression in ovarian cancer were identified and reviewed until December 1, 2015. A meta-an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
5
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 23 publications
0
5
0
Order By: Relevance
“…Stem cell markers have the main function of controlling the embryonal stem cells self-renewal and differentiation and maintaining the biological characteristics [23]. CD44 is a hyaluronic acid receptor and has been found to participate in diverse cellular processes, such as tumor metastasis, cell migration, proliferation [24]. Its elevation has been shown to be correlated to poor prognosis of numerous cancer types [25].…”
Section: Discussionmentioning
confidence: 99%
“…Stem cell markers have the main function of controlling the embryonal stem cells self-renewal and differentiation and maintaining the biological characteristics [23]. CD44 is a hyaluronic acid receptor and has been found to participate in diverse cellular processes, such as tumor metastasis, cell migration, proliferation [24]. Its elevation has been shown to be correlated to poor prognosis of numerous cancer types [25].…”
Section: Discussionmentioning
confidence: 99%
“…An ovarian cancer tissue microarray analysis of paired primary, metastatic and recurrent tumor tissues from 26 patients, demonstrated that the metastatic as well as recurrent ovarian cancer tissues expressed higher levels of CD44 than the primary tumor (14). In addition, a meta-analysis unveiled that patients with CD44 was associated with poor prognosis in ovarian cancer patients, and that a CD44 + status was associated with common clinicopathological features and poor prognostic factors (5).…”
Section: Discussionmentioning
confidence: 99%
“…The prognostic value of CD44 for patients with cancer has been widely validated in various solid tumors, such as hepatocellular carcinoma [37,38], non-small cell lung cancer [39][40][41], gastric cancer [42][43][44][45], ovarian cancer [46][47][48], colorectal cancer [49,50], etc. Some studies have demonstrated that the overexpression of CD44s is a poor prognostic factor for gliomas [51].…”
Section: Introductionmentioning
confidence: 99%